We first performed overall survival analysis to compare the survival of patients harboring mutant or wildtype KRAS in pancreatic adenocarcinoma (PAAD), lung adenocarcinoma (LUAD), and colorectal adenocarcinoma (COAD). Here, KRAS is linked to lung adenocarcinoma.